This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by GREEN, H. D. Articles by DUBOSE, H. H. Search for Related Content PubMed PubMed Citation Articles by GREEN, H. D. Articles by DUBOSE, H. H.

(Circulation. 1954;10:374.)
© 1954 American Heart Association, Inc.

---

Clinical Trial of Ilidar, a New Dibenzazepine Adrenergic Blocking Drug, in the Treatment of Peripheral Vascular Diseases and Miscellaneous Complaints

HAROLD D. GREEN M.D.¹ HUGH H. DUBOSE M.D.¹

¹ From the Department of Physiology and Pharmacology, and the Department of Internal Medicine, Bowman Gray School of Medicine of Wake Forest College, Winston-Salem, N. C.

Ilidar, a new adrenergic blocking drug, has been administered to 116 patients; follow-up was adequate on 86. The drug was highly effective in patients with predominantly vasospastic disorders and in patients with postphlebetic syndrome, and moderately effective in patients with thromboangiitis and arteriosclerosis. Most patients could tolerate 50 to 75 mg. three to four times a day. Side effects were principally those to be expected from the moderate postural hypotension associated with effective sympathetic blockade, namely, weakness, dizziness, nausea.